274 related articles for article (PubMed ID: 25614871)
1. FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry.
Xue Y; Sun A; Mekikian PB; Martin J; Rimoin DL; Lachman RS; Wilcox WR
Mol Genet Genomic Med; 2014 Nov; 2(6):497-503. PubMed ID: 25614871
[TBL] [Abstract][Full Text] [Related]
2. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
3. Novel and Recurrent Mutations in the
Gomes MES; Kanazawa TY; Riba FR; Pereira NG; Zuma MCC; Rabelo NC; Sanseverino MT; Horovitz DDG; Llerena JC; Cavalcanti DP; Gonzalez S
Mol Syndromol; 2018 Feb; 9(2):92-99. PubMed ID: 29593476
[TBL] [Abstract][Full Text] [Related]
4. Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.
Heuertz S; Le Merrer M; Zabel B; Wright M; Legeai-Mallet L; Cormier-Daire V; Gibbs L; Bonaventure J
Eur J Hum Genet; 2006 Dec; 14(12):1240-7. PubMed ID: 16912704
[TBL] [Abstract][Full Text] [Related]
5. p.Ser348Cys mutation in FGFR3 gene leads to "Mild ACH /Severe HCH" phenotype.
Bengur FB; Ekmekci CG; Karaarslan E; Gunoz H; Alanay Y
Eur J Med Genet; 2020 Feb; 63(2):103659. PubMed ID: 31048079
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular diagnosis of the skeletal dysplasias associated with mutations in the gene encoding Fibroblast Growth Factor Receptor 3 (FGFR3) in Portugal.
Almeida MR; Campos-Xavier AB; Medeira A; Cordeiro I; Sousa AB; Lima M; Soares G; Rocha M; Saraiva J; Ramos L; Sousa S; Marcelino JP; Correia A; Santos HG
Clin Genet; 2009 Feb; 75(2):150-6. PubMed ID: 19215249
[TBL] [Abstract][Full Text] [Related]
7. Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family.
Ajmal M; Mir A; Shoaib M; Malik SA; Nasir M
Diagn Pathol; 2017 Jul; 12(1):47. PubMed ID: 28679403
[TBL] [Abstract][Full Text] [Related]
8. High-Resolution Melting Analysis for Rapid Detection of Mutations in Patients with
Riba FRG; Gomes MES; Rabelo NC; Zuma MCC; Llerena JC; Mencalha AL; Gonzalez S
Genet Test Mol Biomarkers; 2021 Oct; 25(10):674-682. PubMed ID: 34672771
[No Abstract] [Full Text] [Related]
9. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
10. Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants.
Chang IJ; Sun A; Bouchard ML; Kamps SE; Hale S; Done S; Goldberg MJ; Glass IA
Am J Med Genet A; 2018 Jul; 176(7):1675-1679. PubMed ID: 30160829
[TBL] [Abstract][Full Text] [Related]
11. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.
Bellus GA; Spector EB; Speiser PW; Weaver CA; Garber AT; Bryke CR; Israel J; Rosengren SS; Webster MK; Donoghue DJ; Francomano CA
Am J Hum Genet; 2000 Dec; 67(6):1411-21. PubMed ID: 11055896
[TBL] [Abstract][Full Text] [Related]
12. Achondroplasia: Development, pathogenesis, and therapy.
Ornitz DM; Legeai-Mallet L
Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
[TBL] [Abstract][Full Text] [Related]
13. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S; Wilcox WR; Krejci P
Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
[TBL] [Abstract][Full Text] [Related]
14. Frequency of the allelic variant c.1150T > C in exon 10 of the fibroblast growth factor receptor 3 (FGFR3) gene is not increased in patients with pathogenic mutations and related chondrodysplasia phenotypes.
Kanazawa TY; Bonadia LC; Cavalcanti DP
Genet Mol Biol; 2014 Oct; 37(4):622-4. PubMed ID: 25505835
[TBL] [Abstract][Full Text] [Related]
15. Low bone mineral density in achondroplasia and hypochondroplasia.
Matsushita M; Kitoh H; Mishima K; Kadono I; Sugiura H; Hasegawa S; Nishida Y; Ishiguro N
Pediatr Int; 2016 Aug; 58(8):705-8. PubMed ID: 26716907
[TBL] [Abstract][Full Text] [Related]
16. Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations.
Alatzoglou KS; Hindmarsh PC; Brain C; Torpiano J; Dattani MT
J Clin Endocrinol Metab; 2009 Oct; 94(10):3959-63. PubMed ID: 19622626
[TBL] [Abstract][Full Text] [Related]
17. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
18. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism.
Bonaventure J; Rousseau F; Legeai-Mallet L; Le Merrer M; Munnich A; Maroteaux P
Am J Med Genet; 1996 May; 63(1):148-54. PubMed ID: 8723101
[TBL] [Abstract][Full Text] [Related]
19. FGFR3-related condition: a skeletal dysplasia with similarities to thanatophoric dysplasia and SADDAN due to Lys650Met.
Farmakis SG; Shinawi M; Miller-Thomas M; Radmanesh A; Herman TE
Skeletal Radiol; 2015 Mar; 44(3):441-5. PubMed ID: 25119967
[TBL] [Abstract][Full Text] [Related]
20. Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia.
Martínez-Frías ML; de Frutos CA; Bermejo E; Nieto MA;
Am J Med Genet A; 2010 Jan; 152A(1):245-55. PubMed ID: 20034074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
